Cardiovascular Impact of Diabetes Meds episode artwork

EPISODE · Apr 1, 2025 · 36 MIN

Cardiovascular Impact of Diabetes Meds

from Medication Talk · host TRC Healthcare

Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits.  We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.Special Guests:Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU HealthChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy PracticeDirector, PGY2 Ambulatory Care Residency ProgramMidwestern University College of Pharmacy, Downers Grove CampusClinical Pharmacist, Northwestern MedicineTRC Editorial Advisory Board Participant:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleFor the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: Chart: Diabetes Medications: Cardiovascular and Kidney ImpactChart: Drugs for Type 2 Diabetes Algorithm: Stepwise Treatment of Type 2 DiabetesChart: Comparison of GLP-1 AgonistsToolbox: Improving Heart Failure CareSend us Fan MailEmail us: [email protected] content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.Learn more about our product offerings at trchealthcare.com.

Episode metadata supplied by the publisher feed · Published Apr 1, 2025

Embed this episode

Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease. Special Guests: Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Cardiovascular Impact of Diabetes Meds

0:00 36:01

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medication Talk?

This episode is 36 minutes long.

When was this Medication Talk episode published?

This episode was published on April 1, 2025.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Medication Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!